首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >What we know and what we don't know about the treatment of schizoaffective disorder.
【24h】

What we know and what we don't know about the treatment of schizoaffective disorder.

机译:关于分裂情感障碍的治疗我们知道什么和不知道什么。

获取原文
获取原文并翻译 | 示例
       

摘要

Schizoaffective disorder (SAD) is a chronic, severe and disabling illness consisting on the concurrent presentation of symptoms of schizophrenia and affective disorders (depression and/or mania). Evidence for the treatment of SAD mostly derives from studies based on mixed samples (i.e. schizophrenic and schizoaffective patients) or on extrapolations from studies on schizophrenia or bipolar disorder. The objective of the present review is to systematically consider and summarize the best evidence-based approaches to the treatment of SAD and extensively point out the gap between treatment research and clinical practice of this disorder. The complex problem of controlling the pleomorphic presentation of SAD's syndromic construct is reflected in the lack of evidence on key topics, including: diagnostic consistency, pharmacological approaches (mood stabilizers, antidepressants, both in acute and maintenance treatment as well as their possible combination), and the adjunctive role of psychosocial and biophysical interventions. Finally, treatment strategies for SAD, both unipolar and bipolar type, are proposed.
机译:精神分裂症(SAD)是一种慢性,严重和致残性疾病,由精神分裂症症状和情感障碍(抑郁和/或躁狂)的并发表现所致。治疗SAD的证据主要来自基于混合样本(即精神分裂症和精神分裂症患者)的研究,或者来自精神分裂症或双相情感障碍研究的推断。本综述的目的是系统地考虑和总结最佳的循证医学方法来治疗SAD,并广泛指出该疾病的治疗研究与临床实践之间的差距。控制SAD综合征结构多态性表现的复杂问题反映在以下关键主题上缺乏证据,包括:诊断一致性,药理学方法(情绪稳定剂,抗抑郁药,用于急性和维持治疗,以及可能的组合),以及社会心理和生物物理干预的辅助作用。最后,提出了单极和双极型SAD的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号